Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EG 011

Next Previous
Drug Profile

EG 011

Alternative Names: Ad-VEGF-D; EG011; VEGF-D short-form

Latest Information Update: 23 Nov 2012

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies; Ischaemic heart disorder therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor D stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Angina pectoris

Most Recent Events

  • 08 Nov 2012 Discontinued - Phase-I/II for Angina pectoris in Finland (Intracoronary)
  • 16 May 2012 Ark Therapeutics completes the phase I portion of its phase I/IIa trial in Angina pectoris in Finland
  • 25 Aug 2011 EG 011 is available for partnering as of 25 Aug 2011. www.arktherapeutics.com

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top